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Leptin is overexpressed in human breast tumors and is produced
by breast cancer cells in response to obesity-related stimuli. The
leptin promoter polymorphism Lep-2548G/A can be associated
with increased leptin secretion by adipocytes and elevated cancer
risk. However, molecular mechanisms underlying the link
between Lep-2548G/A and breast cancer have never been
addressed. Lep-2548G/A is proximal to a binding site for the tran-
scriptional factor Sp1. Furthermore nucleolin, a transcriptional
repressor, can bind Sp1 or its consensus site. Consequently, we
focused on the impact of Lep-2548G/A on Sp1- and nucleolin-
dependent leptin transcription in breast cancer cells. The Lep-
2548G/A was identified in a homozygous conformation in BT-474
and SK-BR-3 breast cancer cells, in a heterozygous conformation
in MDA-MB-231 cells, and a wild-type Lep-2548G/G sequence
was present in MCF-7 and ZR-75-1 cells. The occurrence of Lep-
2548A/A and Lep-2548G/A coincided with high and intermediate
leptin mRNA expression, respectively, while cells containing Lep-
2548G/G expressed low leptin mRNA levels. We demonstrated
that the existence of Lep-2548G/A improved efficient recruitment
of Sp1 to DNA under insulin treatment, while Sp1 loading on
DNA containing Lep-2548G/G was not insulin-dependent. In con-
trast, nucleolin binding to Lep-2548G/A was downregulated in
response to insulin, while it was not regulated on Lep-2548G/G.
The presence of Lep-2548G/A was studied in breast cancer epithe-
lial cells by IHC and LCM. Interestingly, all 14 tumors expressing
high leptin levels contained Lep-2548A/A. In conclusion, the
occurrence of Lep-2548G/A can enhance leptin expression in
breast cancer cells via Sp1- and nucleolin-dependent mechanisms
and possibly contribute to intratumoral leptin overexpression.
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Leptin is an adipose tissue-derived hormone whose main role is
to control appetite and energy balance by acting in the hypothala-
mus. Leptin levels are proportional to fat body mass and are
higher in women than in man.1 In addition, leptin has been shown
to modulate several other processes, such as immune response,
fertility, hematopoiesis.1 In peripheral organs, leptin can act as a
mitogenic, angiogenic, and survival factor.2 Recent studies in cel-
lular and animal models provided strong evidence that leptin can
be involved in neoplastic processes, for instance, in the develop-
ment and progression of breast, colorectal, and endometrial can-
cers.3–5 In addition, both leptin and its receptor (ObR) have been
detected in different neoplastic tissues, usually at levels higher
than that in respective normal tissues.6–8 Interestingly, overexpres-
sion of the leptin system in breast cancer appears to be associated
with higher tumor grade and size.9–13 The mechanisms of leptin
overexpression in breast cancer cells is partially known, for
instance, we have shown that leptin transcription and synthesis
can be induced by hypoxia or high levels of insulin.9,13,14
Here we investigated whether leptin expression in breast cancer
cells could be related to the existence of the Lep-2548G/A poly-
morphism in the promoter region of leptin gene.
Lep-2548G/A has previously been shown to correlate with var-
iations in serum leptin levels, degree of obesity, as well as
cancer.15–17 In particular, studies of Mammes et al. using DNA
from peripheral blood cells documented that the Lep-2548G/A
polymorphism was associated with higher leptin levels independ-
ent of BMI, before and after diet.15 In addition, male, but not
female, subjects with the Lep-2548A/A genotype had higher leptin
concentrations adjusted for fat mass.16 Similar studies suggested
that nonobese women with Lep-2548A/A had higher serum leptin
levels adjusted for body mass index, and significantly higher adi-
pose tissue leptin mRNA expression than did carriers of the wild-
type Lep-2548G/G sequence.17
In the context of neoplastic processes, Lep-2548A/A detected in
DNA from peripheral blood leucocytes associated with increased
risk for non-Hodgkin lymphoma,18 and both Lep-2548A/A and
Lep-2548G/A with non small cell lung cancer as well as prostate
and breast carcinoma.19,20 Furthermore, the existence of Lep-
2548A/A has been shown to correlate with significantly increased
breast cancer risk, and the presence of Lep-2548G/A with interme-
diate risk, compared with the wild-type Lep-2548G/G genotype.21
The Lep-2548G/A polymorphism also correlated with a larger
breast tumor size at diagnosis and a shorter disease-free survival
of patients.21 However, the functional significance of the Lep-
2548G/A polymorphism and its occurrence in cancer tissues has
never been experimentally addressed, and is a subject of this
study.
The human leptin gene promoter (2,500 bp) contains several
consensus binding sites for a variety of transcription factors.22 The
Lep-2548 does not map to any known regulatory site, but is proxi-
mal to an Sp1 binding motif (CCCGCCT; -2539/-2534) that is
known to be regulated by insulin in breast cancer cells.23 Nucleo-
lin is another nuclear factor that can bind a Sp1 consensus site in
the promoter of cytosolic phospholipase A2 (cPLA2)
24 and that
can interact with Sp1, as reported for human keratinocyte (HaCat)
cell extracts.25
Nucleolin is a multifunctional phosphoprotein involved in ribo-
somal RNA transcription, maturation and assembly,26 chromatin
decondensation27 as well as transcriptional regulation,28 including
modulation of Sp1-dependent gene expression.24 Furthermore, in-
sulin may induce changes in the phosphorilation of nucleolin.29
Consequently, we studied in breast cancer cell models if the
occurrence of the Lep-2548G/A polymorphism can enhance basal
and insulin-induced leptin expression via Sp1- and nucleolin-de-
pendent mechanisms. In addition, the existence of the Lep-2548G/
A polymorphism was assessed in breast cancer tissues expressing
high leptin levels using laser capture microdissection.
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Material and methods
Cell culture
MCF-7, MDA-MB-231, SK-BR-3, BT-474, ZR-75-1 cell lines
were purchased from the American Type Culture Collection
(Rockville, MD). MCF-7 and MDA-MB-231 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM:F12) (Cellgro,
Herndon, VA) containing 5% calf serum and 1% Penicillin/Strep-
tomycin (P/S) (Cellgro). SK-BR-3 cells were grown in
DMEM:F12 containing 10% fetal bovine serum (FBS) and 1% P/S.
BT-474 cells were grown in DMEM:F12 containing 10% FBS,
1% P/S and 0.01 lg/ml insulin. ZR-75-1 cells were grown in
RPMI-1640 (BioWhittaker, Walkersville, MD) containing 10%
FBS, 1% P/S and 1mM sodium pyruvate (Cellgro). SK-BR-3
AND ZR-75-1 cell lines were omitted from experiments requiring
serum-free medium (SFM) synchronization because serum deple-
tion induced loss of adhesion and anoikis in these cells.
Detection of the Lep-2548G/A polymorphism
Genomic DNA was extracted from breast cancer cells with
DNeasy Tissue Kit (Qiagen, Hilden, Germany). The existence of
the Lep-2548G/A polymorphism was studied by PCR using a
2700 thermal cycler (Applied Biosystems, Foster City, CA). The
following primers were used: forward 50-ACTTTATAGACACA
GAAATGAAAA-30 reverse 50-AAAATTTATGTTCCTCTGC
CAC-30. The PCR conditions were: 25 cycles at 30 sec at 94C,
30 sec at 53C, 30 sec at 72C. The quality of PCR products was
evaluated in a 2% agarose gel electrophoresis stained with ethi-
dium bromide. Direct sequencing of the PCR products was per-
formed using a BigDye Terminator reaction chemistry on ABI
PRISM 377 Genetic Analyzer (Applied Biosystems). Each genetic
variant was confirmed by direct sequencing of at least two inde-
pendent samples.
Western blotting (WB)
Eighty percent confluent cultures were transferred to phenol
red-free SFM for 24 hr (MCF-7 and MDA-MB-231 cells) or 72 hr
(BT-474) and then stimulated with 2 lg/ml insulin for 3 h, or left
untreated. Because normal growth medium for BT-474 cells con-
tains insulin, this cell line was cultured in SFM for 72 hr to com-
pletely eliminate insulin effects on gene transcription, including
Sp1-mediated regulation.23 Then cells were lysed to separate cyto-
plasmic and nuclear proteins, as described before.30 The expres-
sion of nuclear proteins was analyzed in 200 lg of nuclear cell
lysates. The following antibodies (Abs) were used for WB: Sp1
(PEP2) polyclonal (p)Ab (Santa Cruz Biotechnology, CA), nucle-
olin mAb (Santa Cruz) and c-Jun (N) polyclonal (Santa Cruz).
The proteins were separated on a 4–15% polyacrylamide gel, im-
munoblotted and quantified, as described before.30
Chromatin immunoprecipitation (ChIP)
We followed ChIP methodology described in detail previ-
ously.31 Eighty percent confluent cultures were transferred to SFM
for 24 hr (MCF-7 and MDA-MB-231 cells) or 72 h (BT-474) and
then stimulated with 2 lg/ml insulin for 3 hr, or left untreated.
Following treatment, the cells were crosslinked with 1% formalde-
hyde and chromatin was collected and sonicated. Soluble chroma-
tin was immunoprecipitated with the following Abs: Sp1 PEP2
(Santa Cruz Biotechnology), nucleolin C23 MS-3 (Santa Cruz).
DNA-protein immune complexes were eluted, reverse crosslinked
and DNA was extracted. The binding of Sp1, nucleolin to the lep-
tin promoter region -2632/-2453 containing the -2548 site was
tested using the following primers: forward 50ACTTTATAGACA
CAGAAATGAAAA and reverse 50-CTCGGCACCGTCTCCT
TG-30. The PCR conditions were: 30 cycles at 30 sec at 94C,
30 sec at 53C, 30 sec at 72C. In control samples, the primary
Abs were replaced with appropriate nonimmune IgG.
DNA affinity precipitation assay (DAPA)
Binding of Sp1 and nucleolin to the leptin promoter region con-
taining an Sp1 binding motif and Lep-2548 site was assessed in
vitro using modified DAPA protocol, as described by us before.32
Briefly, nuclear extracts were obtained from cells stimulated or
not with 2 lg/ml insulin for 3 hr. A total of 300 lg of nuclear pro-
teins were mixed with 2 lg of specific biotinylated DNA probes
(see below) in 400 ll of Buffer D (20 mM HEPES pH 7.9, 10%
glycerol, 50 mM KCl, 0.2 mM EDTA, 1.5 mM MgCl2, 10 mM
ZnCl2, 1 mM DTT and 0.25% Triton X100) and then incubated
on ice for 45 min. After that, 50 ll of streptavidin beads (Pierce,
Rockford, IL) were added and the samples were agitated for 2 hr
at 4C. Next, the agarose beads-protein complexes were collected
by brief centrifugation and washed twice in Buffer D. Proteins
were uncoupled from DNA probes by addition of 40 ll SDS load-
ing buffer, and heating at 96C for 10 min. After removal of the
beads, the supernatants were analyzed by WB for the presence of
Sp1 and nucleolin. The specific DNA probes were prepared by
annealing a biotinylated sense oligonucleotide (for -2548G/G: 50-
Bio GGGTTGCGCTGATCCTCCCGCCTCAGTTCCCTA-30 and
for -2548A/A: 50-Bio GGGTTGCACTGATCCTCCCGCCTCAG
TCTCCCTA-30) with nonbiotinylated antisense oligonucleotide
(for -2548G/G: 50-CCCAACGCGACTAGGAGGGCGGAGTCA
GAGGGAT-30 and for -2548A/A: 50-CCCAACGTGACTAGGA
GGGCGGAGTCAGAGGGAT30). Unlabeled probes were used as
negative controls. As an additional control, a 10-fold excess of
unlabeled probes was added to the nuclear lysates 30 min prior to
the addition of the labeled probes to block specific probe-protein
interactions.
Real time-quantitative PCR (Q-PCR)
The cells were synchronized in SFM for 24 hr (MCF-7, MDA-
MB-231) or 72 hr (BT-474) and then treated for 24 hr with 2 lg/
ml insulin. Total cellular RNA was isolated using TRIzol reagent
(Invitrogen, Carlsbad, CA). 5 lg of total RNA was reverse tran-
scribed using the TaqMan RT kit (Applied Biosystems, Branch-
burg, CA) according to vendor’s instructions. 5 ll of the RT prod-
ucts were used to amplify leptin sequences using the Hs00174877
A1 Lep TaqMan kit (Applied Biosystems). To normalize QRT-
PCR reactions, parallel TaqMan b-actin control reagents assays
(Applied Biosystems) were run on each sample. Changes in the
leptin mRNA content relative to b-actin mRNA were determined
using a comparative CT method (ABI User Bulletin no. 2) to cal-
culate changes in CT, and ultimately fold and percent change. An
average CT value for each RNA was obtained for triplicate reac-
tions.
Breast cancer patients and samples
The analysis of leptin gene polymorphism was performed in 14
breast cancer tissue samples, previously identified as strongly lep-
tin-positive.9 Tissue samples were obtained from women who
underwent partial or total mastectomy for primary breast cancer.
The age of patients ranged from 45 to 71 years. Histopathological
examination of sections was based on the WHO and pTN classifi-
cation of breast tumors. Tumor grading (G) was identified as G2
in 78.5% and G3 in 21.5% of cases; node status (N) was identified
as N1 (cancer cells found in one lymph nodes) in 43% and nega-
tive (absence of regional metastases, N0) in 57% of cases. Tumor
size (pT) was identified as pT1 (0–2 cm) in 40% and pT2 (2–5
cm) in 60% of cases. Immediately after excision, tissue samples
were fixed in 10% buffered formaldehyde solution, embedded in
paraffin blocks at 56C.
Laser capture microdissection (LCM) of breast cancer tissue
Sections of 6 lm were cut from breast cancer tissue specimens
paraffin-embedded and mounted on PEN membrane glass slides
(Arcturus, Mountain View, CA). The expression of leptin was
investigated by IHC with specific Abs. Tissue sections were
deparaffinized in xylene and rehydrated in graded series of
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ethanol. After rinsing in PBS, endogenous peroxidase activity was
inhibited by incubation with 30% hydrogen peroxide, diluted in
100% methanol for 30 min at 4C. After three washes in PBS the
sections were incubated with 1.5% blocking serum for 1 hr, then
the sections were incubated for 3 hr with primary antibodies. For
leptin staining, we used the A20 leptin polyclonal Ab (pAb) (Santa
Cruz) at 1:100 dilution, as described before.9 The leptin antigens
were detected with avidin-biotin-peroxidase ABC staining sys-
tems (Santa Cruz). All slides were counterstained with Mayer’s
hematoxylin. Areas of interest were collected using a Veritas
(Arcturus, Mountain View, CA) LCM instrument equipped with
Veritas image archiving software. The cutting beam diameter was
2.0 lm and the capture beam diameter was 7.0–9.0 lm. The laser
intensity control was set at 4.0 mV for cutting and 200 mV for
capture. Typically, 6–8 laser pulses were required to cut out the
selected area, which was then captured on thermoplastic film
coated CapSureTM Macro Caps mounted films (Arcturus) accord-
ing to manufacturer’s directions. Portions of the films holding cap-
tured areas were placed in microcentrifuge tubes and used for
DNA extraction performed with PicoPure DNA Extraction Kit
(Arcturus). Detection of the Lep-2548G/A polymorphism was per-
formed as described above.
Results
Detection of the Lep-2548G/A polymorphism
in breast cancer cell lines
Genotypes were determined for different breast cancer cell lines
to test if the occurrence of the Lep-2548G/A polymorphism in the
leptin promoter can enhance basal and insulin-induced leptin
expression. MCF-7 and ZR-75-1 cells contained the wild type
(Lep-2548G/G) promoter sequence, MDA-MB-231 cells con-
tained heterozygous (Lep-2548G/A) variant, while BT-474 and
SK-BR-3 cells were homozygous for the (Lep-2548A/A) polymor-
phism (Fig. 1). MCF-7, MDA-MB-231 and BT-474 cells were
selected for further experiments.
Interaction between Sp1, nucleolin and the leptin promoter
domain containing the Lep-2548 site
The Lep-2548 site doesn’t map to any known regulatory site,
but is proximal to an Sp1 binding motif (CCCGCCT; -2539/
-2534). We recently reported that this leptin promoter region is
regulated by Sp1 in an insulin-dependent fashion in MDA-MB-
231 cells.23 Interestingly, a Sp1-binding sequences of the cytosolic
phospholipase A2 promoter seem to be also recognized by another
transcriptional regulator, nucleolin.24 It has also been proved a
protein-protein interaction between Sp1 and nucleolin in human
keratinocyte (HaCat) cell extracts.25 Here we investigated how the
presence of the Lep-2548G/A polymorphism might affect insulin-
dependent leptin transcription.
First, we determined basal and insulin-induced nuclear expres-
sion levels of Sp1 and nucleolin in different breast cancer cell
lines (Fig. 2). The abundance of Sp1 and nucleolin in the nuclei of
MCF-7, MDA-MB-231 and BT-474 cells varied depending on cell
line, but in each case was not affected by insulin addition (Fig. 2).
Next, we investigated, by ChIP assays, the binding of Sp1 and
nucleolin to the Lep-2548 region using native chromatin of MCF-
7, MDA-MB-231 and BT-474 cell lines (Fig. 3a). We found that,
under insulin treatment, the presence of the polymorphism
improves Sp1 binding to the promoter, while it reduces nucleolin
association in MDA-MB-231 (Lep-2548G/A) and BT-474 (Lep-
2548A/A) cells. In MCF-7 (Lep-2548G/G) we did not observe any
regulation of Sp1 or nucleolin under insulin treatment. Chromatin
samples precipitated with control antibodies did not reveal any
PCR products for Lep-2548 region (data not shown).
To specifically map Sp1 and nucleolin binding site within the
ChiP-tested DNA region, we used DAPA protocol. Short biotinyl-
ated DNA probes containing a Sp1 binding motif adjusted to Lep-
2548A/A or Lep-2548G/G sequences were hybridized with
FIGURE 1 – Detection of the Lep-2548G/A polymorphism in breast cancer cells. Presence of the Lep-2548G/A polymorphism was assessed
by direct sequencing in five different breast cancer cell lines: MCF-7 and ZR-75-1 cells displayed a wild type (Lep-2548G/G) genotype, MDA-
MB-231 cells were heterozygotic (Lep-2548G/A), and SK-BR-3 and BT-474 cells were homozygotic for the polymorphism (Lep-2548A/A).
FIGURE 2 – Expression of Sp1 and nucleolin in breast cancer cell
lines. The expression of nuclear Sp1 and nucleolin (Nuc) was ana-
lyzed by WB, as described in Material and methods section, in 200 lg
of nuclear proteins obtained from cells treated with 2 lg/ml insulin
(Ins) for 3 hr, or left untreated. Protein loading was controlled by
reprobing the WB filter for the expression of a nuclear marker c-Jun.
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nuclear proteins obtained from MDA-MB-231 cells, stimulated or
not with 2 lg/ml insulin. Confirming ChIP results, we found that
the Lep-2548A/A genotype improves recruitment of Sp1 to DNA
under insulin treatment, while it reduces the recruitment of nucle-
olin. In contrast, binding of nucleolin was not regulated on the
wild type Lep-2548G/G (Fig. 3b). Unlabeled probes, used as con-
trols, did not precipitated Sp1 or nucleolin proteins (data not
shown).
Differential leptin mRNA expression in breast cancer cells
carrying different Lep-2548 genotypes
To assess whether the presence of Lep-2548G/A and differen-
tial binding of Sp1 and nucleolin to this site can be associated
with differential leptin transcription, we used QRT-PCR to mea-
sure basal and insulin-induced leptin mRNA levels in MCF-7,
MDA-MB-231 and BT-474 cells. The lowest levels of basal leptin
mRNA were found in MCF-7 cells (Lep-2548G/G), intermediate
levels in MDA-MB-231 cells (Lep-2548G/A), and the highest lev-
els in BT-474 cells (Lep-2548A/A) (Fig. 4). Treatment with 2 lg/
ml insulin did not significantly modulate leptin expression in
MCF-7 cells (Lep-2548G/G), relative to basal expression, while
enhanced leptin mRNA levels in MDA-MB-231 cells (Lep-
2548G/A). In BT-474 cells (Lep-2548A/A) expressing high basal
leptin mRNA insulin addition did not significantly modulate leptin
expression (Fig. 4).
Detection of the Lep-2548G/A polymorphism
in breast cancer tissues
We performed preliminary analysis of leptin promoter polymor-
phism in human breast cancer biopsies. Leptin expression in the
cancer tissues studied was previously identified as very high
(111 score).9 In this analysis, we confirmed by specific IHC
staining high leptin expression in the selected tumors. The leptin-
expressing epithelial cells were isolated by laser microdissection
(LCM). Analysis of DNA from the leptin overexpressing cancer
tissues revealed the presence of the Lep-2548A/A polymorphism
in all samples.
Discussion
The common Lep-2548G/A polymorphism in the leptin gene
promoter has previously been associated with degree of obesity,
variations in serum leptin levels, and leptin synthesis by adipose
tissue.15 New data suggested the link between Lep-2548G/A and
risk of neoplastic disease.18–21
Studies in cellular and animal models strongly suggested that
high levels of leptin might promote breast carcinogenesis.3
Reports from our and other laboratories demonstrated that both
leptin and ObR are overexpressed in breast cancer cells,4,6,33
which implies that leptin could promote breast cancer not only
through endocrine but also through autocrine mechanisms. As
reported by us before, leptin synthesis in breast cancer cells can be
upregulated by obesity-related stimuli, such as high levels of insu-
lin, insulin-like growth factor I, or estrogens.9,23,34 However, the
possibility that leptin promoter poymorphism might influence lep-
tin transcription in breast cancer cells have never been studied.
FIGURE 3 – Interaction between Sp1, nucleolin and the leptin promoter domain containing the Lep-2548 site. (a) The binding of Sp1 and
nucleolin (Nuc) to the leptin promoter region containing an Sp1 binding motif and the Lep-2548 site was tested by ChIP, as described in Mate-
rial and methods section. Cells were transferred to SFM for 24 hr (MCF-7 and MDA-MB-231 cells) or 72 hr (BT-474) and then stimulated with
2 lg/ml insulin for 3 hr. In control samples, the primary Abs were replaced with nonimmune IgG (not shown). (b) The binding of Sp1 and nucle-
olin (Nuc) to the leptin promoter region containing an Sp1 site and the Lep-2548 sequence was assessed in vitro using modified DAPA, as
described in Material and methods section. MDA-MB-231 cells were transferred to SFM for 24 hr and then stimulated with 2 lg/ml insulin for
3 hr. Next, 300 lg of nuclear protein were mixed with 2 lg of specific biotinylated DNA probes for Lep-2548G/G or Lep-2548A/A and nonbio-
tinylated antisense oligonucleotides, as detailed in Material and methods section. Control nonbiotinylated probes did not produce any Sp1 or
nucleolin binding (not shown).
FIGURE 4 – Leptin mRNA expression in breast cancer cell lines
with different genotype for the Lep-2548 polymorphism. The abun-
dance of leptin mRNA was studied using QRT-PCR in MCF-7, MDA-
MB-231 (MDA) and BT-474 (BT) cells untreated or treated with
2 lg/ml insulin (Ins) for 24 hr, as described in Material and methods
section. The graphs represent the increase of leptin mRNA relative to
the increase of constitutive mRNA control (b-actin) in the same sam-
ple 6 SDs. The differences between the two conditions (untreated and
treated) were statistically significant (p < 0.05).
1041LEP-2548G/A IN BREAST CANCER
Until now, the molecular basis of the link between the occur-
rence of Lep-2548G/A and increased leptin expression have not
been investigated. One report implied, however, that some tran-
scriptional events can be involved: electric mobility shift assay
revealed that nuclear extracts from human monocyte U937 cells
form a protein-DNA complex with the polymorphic site Lep-
2548G/A, binding with higher affinity to the Lep-2548A allele.17
However, using nuclear proteins from human subcutaneous adipo-
cytes, two complexes were found, one with the same mobility as
the protein complex derived from U937 cells and the other with
higher mobility. The molecular composition of these two com-
plexes has not been described.17
Here we investigated if human breast cancer cells contain the
Lep-2548G/A polymorphism and if the presence of this variant
can affect leptin gene expression. Because the Lep-2548G/A site
in the leptin promoter is proximal to Sp1 binding motif23 and
nucleolin could interact with Sp125 and bind his consensus sites,24
we focused on the interplay between Lep-2548G/A and the two
transcriptional regulators in the process of basal and insulin-
induced leptin mRNA synthesis.
We first identified three different Lep-2548 genotypes in breast
cancer cell lines. Specifically, MCF-7 and ZR-75-1 cells contained
the Lep-2548G/G wild-type genotype, while MDA-MB-231 con-
tained the Lep-2548G/A polymorphism, and BT-474 and SK-BR-
3 cells expressed the Lep-2548A/A genotype. ChIP assays sug-
gested that in MCF-7 cells, basal binding of Sp1 or nucleolin to
Lep-2548G/G was not affected by insulin treatment. On the other
hand, in MDA-MB-231 and BT-474 cells, insulin induced Sp1
binding and reduced nucleolin association with Lep-2548G/A and
Lep-2548A/A, respectively (Fig. 5). The differential binding of
Sp1 and nucleolin to Lep-2548G/G and Lep-2548A/A was con-
firmed by DAPA assays (Fig. 3b). These results suggested that the
presence of Lep-2548A/A and Lep-2548G/ A sequences might
increase insulin-dependent activation of the leptin promoter by
promoting the exchange between the negative transcriptional regu-
lator nucleolin and the positive regulator Sp1 (Fig. 5). Based
on these results, one could speculate that Lep-2548 sequence
variations in the leptin gene promoter might contribute to the
FIGURE 5 – Detection of the Lep-2548G/A polymorphism in breast
cancer tissues. Before LCM experiment, the expression of leptin in
each tissue sample was visualized by IHC with specific Abs and all
slides were counterstained with Mayer’s hematoxylin. The areas
before and after capture, as well as captured areas were photo-
graphed using Veritas image archiving software. Three representa-
tive LCM experiments (1, 2, 3) are shown. Arrows indicate leptin-
positive areas.
FIGURE 6 – Model of functional interactions at the Lep-2548 site. Hypothetical model of Sp1/nucleolin binding to the Lep-2548 region in
MCF-7, MDA-MB-231 and BT-474 cells untreated (SFM) or treated with insulin (Ins) is presented. The presence of an A allele (Lep-2548G/A,
Lep-2548A/A) improves efficient recruitment of Sp1 to DNA under insulin treatment. In contrast, binding of nucleolin to Lep-2548G/A or Lep-
2548A/A is downregulated in response to insulin, while it is not regulated on Lep-2548G/G.
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differences in leptin mRNA expression observed in different
breast cancer cell lines. Indeed, the lowest levels of basal leptin
mRNA were found in MCF-7 cells (Lep-2548G/G), intermediate
levels in MDA-MB-231 cells (Lep-2548G/A), and the highest lev-
els in BT-474 cells (Lep-2548A/A) (Fig. 4). Interestingly, MCF-7
cells are characterized by low aggressive, metastatic phenotype,
while BT-474 and SK-BR-3 are of a more aggressive phenotype.35
Whether or not the expression of leptin in these cells might deter-
mine the degree of their malignancy is not yet known.
It is noteworthy, however, that the leptin promoter contains
multiple transcription regulatory motifs regulated by insulin. For
instance, seven Sp1 sites, and 8 elements binding HIF.22,35,36 Our
previous study demonstrated that in MDA-MB-231 cells treated
with insulin, Sp1 acts through two sites, one of which is in Lep-
2548 region. On the other hand, functional insulin-regulated Sp1
sites in the leptin promoter have not been mapped in other cells
lines. Thus, except for MDA-MB-231 cells, the relative impor-
tance of Lep-2548 to basal and insulin-induced leptin expression
is difficult to measure in other cells. The possible involvement of
multiple transcription mechanisms could explain the very high ba-
sal leptin mRNA expression in BT-474 cells and the lack of appre-
ciable insulin-induced stimulation in these cells, despite the appa-
rent activation of the Lep-2548 site. Moreover, it has to be noted
that concentrations of insulin used in our study are relatively high
(to mimic, at least to some extent) the conditions of hyperinsulin-
emia. These conditions might lead to activation not only insulin
receptors but also receptors for IGF-1 as well as hybrids insulin/
IGF-IR.37,38
The presence of Lep-2548G/A and A/A polymorphism in breast
cancer cells lines prompted us to investigate whether this genotype
can be found in breast tumors. Using LCM, we extracted leptin-
positive cancer areas from breast tumors and sequenced DNA of
cancer cells (Fig. 6). Interestingly, in all cases, cancer cells con-
tained the Lep-2548A/A polymorphism. The predominance of the
Lep-2548A/A genotype might be related to the fact only tumors
expressing leptin at high levels were studied. It is possible that
more genotypic variability would be detected in greater number of
cases characterized by various degrees of leptin expression.
In conclusion, our study suggests that the Lep-2548G/A poly-
morphism, previously detected in PBC and associated with
increased leptin synthesis, occurs in breast cancer cell DNA and
could contribute to leptin overexpression in this cellular context.
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